| Literature DB >> 31881666 |
Sirma Angelova1, Ayshe Salim2, Yoana Kiselova-Kaneva2, Diana Ivanova2, Stefan Peev3.
Abstract
Nowadays, saliva is a subject of growing scientific interest because of its definite advantages as diagnostic medium. The aim of our study was to investigate the diagnostic potential and reliability of messenger RNAs (mRNAs) of selected genes-interleukin-6 (IL-6), matrix metalloproteinase-8 (MMP-8) and glutathione synthetase (GSS)-as salivary markers in children with diagnosed pyelonephritis and to correlate their levels with typical urine para-clinical indicators of the disease. Analysis of the mRNA levels for IL-6, MMP-8 and GSS in 28 children hospitalized with the diagnosis of pyelonephritis was conducted applying the method of quantitative reverse transcription polymerase chain reaction (RT-qPCR). In the study group (n = 28), IL-6 mRNA levels demonstrated 64-fold increase (p < 0.001). MMP-8 and GSS mRNA levels were increased in 12 samples in patients with pyelonephritis 3.27 (p < 0.01) and 1.94 (p < 0.001) times, respectively. We found a strong and significant correlation (p < 0.001) between the investigated mRNA for IL-6 and MMP-8, IL-6 and GSS, MMP-8 and GSS. Moderate degree of correlation was established between IL-6 and the typical para-clinical indicator of leucocytes (0.43, p < 0.05) and between GSS and leucocytes (0.54, p < 0.01). Salivary IL-6, MMP-8 and GSS mRNA levels in combination with urine test analysis could be useful diagnostic tool for the very distributed disorder of pyelonephritis in childhood.Entities:
Keywords: GSS; MMP-8; children; correlation; mRNA levels; pyelonephritis; salivary biomarkers of IL-6
Mesh:
Substances:
Year: 2019 PMID: 31881666 PMCID: PMC6982834 DOI: 10.3390/molecules25010085
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Mean fold-change of interleukin-6 (IL-6), matrix metalloproteinase-8 (MMP-8), glutathione synthetase messenger RNA (GSS mRNA) levels for the total investigated group of 28 children with diagnosed pyelonephritis. All fold changes are presented as mean for the total group versus a control group of nine children with no common health disorders. The expression of each gene of interest in the control group is considered to be equal to 1. Expression levels are presented in relative units (RU) ± SEM and human β-actin was used as endogenous control to normalize mRNA levels of IL-6, MMP-8 and GSS in each sample. ** p < 0.01 versus control group; *** p < 0.001 versus control group; ns—not significant.
Figure 2MMP-8 mRNA levels in saliva of 28 children with diagnosed pyelonephritis. Expression levels are presented in relative units ± SEM versus human β-actin as endogenous control. * p < 0.05 versus control group; ** p < 0.01 versus control group; *** p < 0.001 versus control group; ns—not significant.
Figure 3GSS mRNA levels in saliva of 28 children with diagnosed pyelonephritis. Expression levels are presented in relative units ± SEM versus human β-actin as endogenous control. * p < 0.05 versus control group; ** p < 0.01 versus control group; *** p < 0.001 versus control group; ns—not significant.
Figure 4IL-6 mRNA levels in saliva of 28 children with diagnosed pyelonephritis. Expression levels are presented in relative units ± SEM versus human β-actin as endogenous control. * p < 0.05 versus control group; ** p < 0.01 versus control group; *** p < 0.001 versus control group; ns—not significant.
Descriptive analysis of anamnestic data and para-clinical urine indicators for all 28 children with pyelonephritis.
| Patient | Urine Analysis Indicators | Family Anamnesis for Kidney Diseases | Occurrence/Recurrence of Kidney Disorder | ||
|---|---|---|---|---|---|
| Proteins | Blood | Leucocytes | |||
| 12 | trace < 30 mg/dL | 250 Ery/µL | +++ | None | Primary patient |
| 28 | + | 50 Ery/µL Hemolysis | +++ | None | Chronical kidney disease, in condition of exacerbation |
| 7 | 0 mg/dL | 10 Ery/µL Non-Hemolysis | +75 Leuc/µL | Father—with kidney aplasia (lack of one of the kidneys); brother- with significant bacteriuria; | Primary patient |
| 17 | trace < 30 mg/dL | 50 Ery/µL Non-Hemolysis | 25 Leuc/µL | None | Primary patient |
| 4 | 0 mg/dL | negative | 25 Leuc/µL | None | Primary patient |
| 16 | 0 mg/dL | 250 Ery/µL Non-Hemolysis | + 75 Leuc/µL | None | Chronical kidney disease, in condition of exacerbation |
| 11 | trace < 30 mg/dL | 50 Ery/µL Non-Hemolysis | + 75 Leuc/µL | Sister—congenital anomaly of the excretory system (lack of one kidney) | Chronical kidney disease, in condition of exacerbation |
| 23 | 0 mg/dL | 10 Ery/µL Non-Hemolysis | 25 Leuc/µL | None | Chronical kidney disease, in condition of exacerbation |
| 19 | +30–100 mg/dL | 50 Ery/µL Hemolysis | + 75 Leuc/µL | None | Primary patient |
| 10 | trace < 30 mg/dL | 50 Ery/µL Non-Hemolysis | + 75 Leuc/µL | None | Primary patient |
| 6 | trace < 30 mg/dL | 10 Ery/µL Non-Hemolysis | 25 Leuc/µL | None | Chronical kidney disease, in condition of exacerbation |
| 5 | trace < 30 mg/dL | 250 Ery/µL | + 75 Leuc/µL | None | Primary patient |
| 2 | trace < 30 mg/dL | 50 Ery/µL Non-Hemolysis | + 75 Leuc/µL | None | Primary patient |
| 1 | trace < 30 mg/dL | 250 Ery/µL | + 75 Leuc/µL | Mother with nephrolithiasis | Primary patient |
| 24 | trace < 30 mg/dL | 50 Ery/µL Non-Hemolysis | + 75 Leuc/µL | Father with non-diagnosed kidney disorder | Chronical kidney disease, in condition of exacerbation |
| 27 | +30–100 mg/dL | 5-10 Ery/µL Hemolysis | + 75 Leuc/µL | None | Primary patient |
| 21 | trace < 30 mg/dL | 50 Ery/µL Non-Hemolysis | + 75 Leuc/µL | None | Primary patient |
| 25 | trace < 30 mg/dL | 50 Ery/µL Non-Hemolysis | + 75 Leuc/µL | None | Primary patient |
| 26 | trace < 30 mg/dL | 50 Ery/µL Hemolysis | + 75 Leuc/µL | Aunt with kidney agenesia; cousin suffering from pyelonephrithis | Chronical kidney disease, in condition of exacerbation |
| 3 | trace < 30 mg/dL | 10 Ery/µL Non-Hemolysis | 25 Leuc/µL | None | Chronical kidney disease, in condition of exacerbation |
| 8 | trace < 30 mg/dL | 50 Ery/µL Non-Hemolysis | 25 Leuc/µL | Grandfather and father suffering from nephrolithiasis | Chronical kidney disease, in condition of exacerbation |
| 9 | trace < 30 mg/dL | 25 Ery/µL Hemolysis | 25 Leuc/µL | Grand-grandfather and grandfather suffering from nephrolithiasis | Chronical kidney disease, in condition of exacerbation |
| 14 | +30–100 mg/dL | 50 Ery/µL Hemolysis | + 75 Leuc/µL | Aunt suffering from renal failure; mother with diagnosed pyelonephritis | Chronical kidney disease, in condition of exacerbation |
| 22 | trace < 30 mg/dL | 250 Ery/µL | +++ 500 Leuc/µL | None | Chronical kidney disease, in condition of exacerbation |
| 20 | trace < 30 mg/dL | 5–10 Ery/µL Hemolysis | 25 Leuc/µL | None | Primary patient |
| 13 | +30–100 mg/dL | 5–10 Ery/µL Hemolysis | + 75 Leuc/µL | None | Primary patient |
| 15 | trace < 30 mg/dL | 50 Ery/µL Non-Hemolysis | 25 Leuc/µL | None | Chronical kidney disease, in condition of exacerbation |
| 18 | trace < 30 mg/dL | 250 Ery/µL | + 75 Leuc/µL | Grandmother suffering from nephrolithiasis | Chronical kidney disease, in condition of exacerbation |
Each patient identified as suffering from chronical pyelonephritis is in condition of exacerbation at the moment of registration of the determined indicators. Patients included in Table 1 are presented in a descending order based on the values of the indicator salivary IL-6. IL-6 is considered as an essential marker of acute inflammatory processes, as well as of exacerbation of chronical inflammation.
Coefficient of Correlation by Pearson’s between Salivary Biomarkers and Para-clinical Indicators from Urine Assay.
| Leu |
| Blood |
| IL-6 |
| GSS |
| MMP-8 |
| |
|---|---|---|---|---|---|---|---|---|---|---|
|
| - | - | 0.45 | <0.05 | 0.43 | <0.05 | 0.54 | <0.01 | 0.72 | <0.001 |
| Blood | 0.45 | <0.05 | - | - | 0.15 | ns | 0.20 | ns | 0.30 | ns |
| IL-6 | 0.43 | <0.05 | 0.15 | ns | - | - | 0.75 | <0.001 | 0.75 | <0.001 |
| GSS | 0.54 | <0.01 | 0.20 | ns | 0.75 | <0.001 | - | - | 0.86 | <0.001 |
| MMP-8 | 0.72 | <0.001 | 0.30 | ns | 0.75 | <0.001 | 0.86 | <0.001 | - | - |
The values of Pearson’s coefficient in the range between 0.00 and 0.25 correspond to slight correlation. The values in the range from 0.26 to 0.49 are associated with moderate correlation. Levels of the coefficient from 0.50 to 0.69 are related to considerable correlation. The values from 0.70 to 0.89 characterize strong correlation. The values from 0.90 to 1.00 are characteristic of a very strong correlation. p-values < 0.05 were considered statistically significant.